molmed.it
MolMed S.p.A.MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
http://www.molmed.it/
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
http://www.molmed.it/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
0.5 seconds
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
0
SITE IP
176.58.106.33
LOAD TIME
0.484 sec
SCORE
6.2
MolMed S.p.A. | molmed.it Reviews
https://molmed.it
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
molmed.it
MolMed S.p.A.
http://www.molmed.it/node/2698
Our goal is to provide physicians and patients with innovative and effective therapies for the treatment of cancers for which current treatment options are limited. To achieve this, we are carrying out clinical trials on two distinct investigational therapies, both new and complementary to each other, completely original founders of new therapeutic classes:. Main results of clinical trials. Cell and Gene therapy. SpA Via Olgettina, 58 - 20132 Milano, Italy. Phone 39 0221277.1 - Fax 39 02 21277.325.
MolMed S.p.A.
http://www.molmed.it/publications
Cell and Gene Therapy. Tumor targeting and treatments. Angewandte Chemie (International ed. in English). Annals of the New York Academy of Sciences. Biology of Blood and Marrow Transplantation. British Journal of Cancer. Current Drug targets. Immune Endrocrine and Metabolic Disorders. European Journal of Cancer. Expert Opinion on Biological Therapy. Hematology and Cell Therapy. International Journal of Cancer. International Journal of Hematology. Journal of Biological Chemistry. Journal of Drug Targeting.
MolMed S.p.A.
http://www.molmed.it/node/1866
The best treatment currently available for leukaemias and other haematological malignancies is the transplant of haematopoietic stem cells (HSCT) from healthy donors. However, fully compatible donors are available only for approximately 50% of patients. TK is an ex vivo cell therapy, enabling safe HSCT from partially compatible haplo-identical donors (e.g. mother, father, brothers or sisters), who are available for nearly all patients. Administration of TK therapy following HSCT promotes early and sustai...
MolMed S.p.A.
http://www.molmed.it/node/23
Through scientific innovation, MolMed. Continuously develops in-house expertise in cell/genetic engineering and in peptide-targeted technology. Cell and Gene therapy. Aug 22, 2016. The European Commission grants a Conditional Marketing Authorisation to Zalmoxis. Aug 1, 2016. The Board of Directors approves the first half-year financial report ended June 30, 2016. Jul 1, 2016. MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis(R). Subscribe to press releases.
MolMed S.p.A.
http://www.molmed.it/node/70
S business strategy strongly relies on establishing strategic alliances with major biotech and pharmaceutical companies, in order to foster the development of its leading products through co-development, co-marketing or out-licensing partnerships. Intends to out-license some of its leading products for selected indications and territories:. NGR-hTNF vascular targeting agent. Offers out-licensing of a novel therapeutic gene ,. Aug 22, 2016. Aug 1, 2016. Jul 1, 2016. Subscribe to press releases. E-mail: bu...
TOTAL PAGES IN THIS WEBSITE
19
www.molmed-goettingen.de
AMGP: Ajou University Molecular Medicine Graduate Program
Research Highlights @ ANGP. Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species (International Jour. 박선 교수 연구팀, 은나노입자가 활성산소 생산을 통해 당대사에 변화를 초래함을 밝힘). Silver nanoparticles (AgNPs) affect glucose metabolism. International Conference of the Korean Society for Molecular and Cellular Biology. 구기방 통합과정 학생이 국제학술대회 [아모레퍼시픽 차세대 연구자] 상을 수상하여 이백만원의 상금을 받았으며 연구내용을 발표 함. 이광 교수 연구팀, 실리카 코팅 자성 나노입자 의 통합오믹스적 나노독성 분석). Immunobiology. 2015, 220(12):1381-92). Cell-...
پزشکی در سطح مولکول
پزشکی در سطح مولکول. بیماری پارکینسون در اثر تحلیل سلولهای مغزی در سنین بالای 60 سال رخ میدهد و تقریبا 66% بیماران طی 5 سال اول بیماری و 80% پس از 10 سال دچار ناتوانی میگردند. پارکینسن یک بیماری دژنراتیو عصبی، ناتوانکننده و پیشرونده است که توسط جیمزپارکینسون در سال 1817 توصیف شد. مشخصات بیماری عبارتند از حرکت کند و کاهش یافته، سفتی و لرزش عضلانی و عدم تعادل، جویدن ناقص، اختلال در بلع و در سخن گفتن. سه فرضیه در مورد علت شناسی پارکینسون وجود دارد:. تغییر متابولیسم دوپامین در اثر یک جراحت عصبی. در حال حاضر ...
MolMed S.p.A.
Alliance for Regenerative Medicine. Luca Alberici, Ph.D.,. Professor Mohamad Mohty (EBMT President) at the 58th Annual Meeting of the American Society of Hematology (ASH). SpA is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer. Apr 17, 2018. 6th Annual Cell and Gene Therapy Investor Day 17 april NY. Apr 3, 2018. Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri. Feb 1, 2018.
molmed.humanmedizin-goettingen.de
Diese Domain wurde bei EDIS registriert! DE
Webhosting und vserver in Österreich, Deutschland, Schweiz, England, Italien, USA, Frankreich, Island, Poland, Spanien, Chile, Hongkong, Isle of Man, . Ist Ihre Wunschdomain noch verfügbar? PHP7 Webhosting Oesterreich mit der besten e-Mail-Sicherheitsloesung der Welt. Let's Encrypt SSL Zertifikate. Enterprise Dedicated Server HP Proliant DL360 Vienna Austria.
MolMed S.p.A.
Alliance for Regenerative Medicine. Luca Alberici, Ph.D.,. Professor Mohamad Mohty (EBMT President) at the 58th Annual Meeting of the American Society of Hematology (ASH). SpA is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer. Apr 17, 2018. 6th Annual Cell and Gene Therapy Investor Day 17 april NY. Apr 3, 2018. Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri. Feb 1, 2018.
東京都医学総合研究所 分子医療PT of MolMed Research
7月 8日 感染症サイトカイン研究会 神戸 世話人会 松田浩珍先生発表. 6月30日 7月1日 第17回CBSM 大会長 医学研 芝崎 太 が伊豆熱海で開催されます。 5月23日 NGS学会 大保木 仙台. 5月15日 東京理科大理工学部講義 2 芝崎. 5月14日 医学研 連係大学院説明会 医学研. 5月12日 TOBIRA主催 第6回研究フォーラム お茶の水 ソラシティー. 5月 8日 東京理科大理工学部講義 1 芝崎. 4月 1日 新しく後藤紗季、入江 敦の二名の常勤研究員が当研究プロジェクトに加わりました。 組合 とびら)、主催権研究会としてConference for BioSignal and Medicine CBSM)を毎年開催しております。
Molekulare Medizin - Universität Erlangen - Molekulare Medizin - Universität Erlangen
Allgemeine Informationen zum Studienprogramm. To-Do-Liste für Erstsemester (Bachelor). To-Do-Liste für Erstsemester (Master). The old order changeth, yielding place to the new.". Alfred Lord Tennyson (1886). Auf der Webseite des B.Sc./M.Sc. Studienprogramms. Please update your Flash Player. Montag, 12.10.2015 um 08:00. Studienbeginn Bachelor Molekulare Medizin. Wir freuen uns darauf, Sie im Oktober kennen zu lernen! Montag, 12.10.2015 um 08:00. Studienbeginn Master Molekulare Medizin.
Welcome to Molecular Medicine, Department of Medical Sciences - Uppsala University, Sweden
Department of Medical Sciences. Prof Ann-Christine Syvänen. Ann-Christine.Syvanen@medsci.uu.se. Department of Medical Sciences. For additional contact information. Welcome to Molecular Medicine, Department of Medical Sciences. In Molecular Medicine headed by Professor Ann-Christine Syvänen was started in 1998. The group studies human diseases using modern technology for genomics. Professor Syvänen also heads the SNP&SEQ Technology Platform. Use the tab-menu above to view information about our research.
Erasmus MC - Molecular Medicine Post Graduate School
Home - Molecular Medicine
Springer Nature BMC: A New Partnership. The Feinstein Institute is now publishing. In cooperation with BioMed Central, part of Springer Nature (December 2017). Journal information and submission instructions can now be found on BioMed Central.
